New drug BI 3031185 put to the test: safety check and birth control interaction study

NCT ID NCT07656792

Recruiting now Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This early-stage trial investigates the safety and tolerability of a new drug called BI 3031185 in healthy Japanese men, given as single or multiple doses. It also examines whether multiple doses of BI 3031185 affect how the body processes a common oral contraceptive (YAZ®) in healthy Japanese women. The study aims to gather crucial safety data and understand potential drug interactions before moving to larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 3031185
What this could lead to: If successful, this could pave the way for future studies of BI 3031185 in treating diseases, by first confirming it is safe and does not interfere with common medications.
What could go wrong: This is an early phase 1 trial in healthy volunteers, not patients. The drug may prove unsafe or ineffective in later trials. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Fukuoka Mirai Hospital
RECRUITING

Fukuoka, Fukuoka, 813-0017, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.